Medicine/Health

From Pets to People: Canine Eyedrop Study Offers Insights for  Human Eye Care

From Pets to People: Canine Eyedrop Study Offers Insights for Human Eye Care

9 April, 2025

A promising new discovery from the Hebrew University of Jerusalem reveals that cross-linked hyaluronic acid (XHA) significantly enhances the retention and concentration of topical antibiotics in the tear film of dogs. Compared to traditional formulations using polyvinyl alcohol (PVA), the XHA-based eyedrops maintained higher drug levels for longer durations. This innovation not only suggests improved treatment outcomes for veterinary patients – it also carries meaningful implications for human medicine.


 

Spinning Into Resistance: The Flagella’s Hidden Role

Spinning Into Resistance: The Flagella’s Hidden Role

8 April, 2025

A new study from the Hebrew University of Jerusalem reveals that bacterial movement plays a central role in the transfer of antibiotic resistance genes. The research team discovered that the rotation of flagella in Bacillus subtilis acts as a mechanical signal that activates key conjugation genes. This enables donor bacteria to form clusters with recipients and successfully transfer DNA in liquid environments. The findings suggest that bacteria can use motion to control when and where gene sharing occurs, offering new insight into the spread of resistance across species.

Potential Treatment for Chronic Kidney Disease in Dogs Revealed

Potential Treatment for Chronic Kidney Disease in Dogs Revealed

20 March, 2025

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in Journal of Veterinary Internal Medicine, offers new hope for the management of chronic kidney disease (CKD) in dogs. The research highlights the potential benefits of paricalcitol, a second-generation vitamin D analog, in addressing renal secondary hyperparathyroidism (RHPT) and proteinuria—two critical complications of CKD.


 

Lung Cancer Research Foundation Announces Research Collaboration with Israel Cancer Research Fund Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew University

Lung Cancer Research Foundation Announces Research Collaboration with Israel Cancer Research Fund Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew University

19 February, 2025

The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on a project led by Joel Yisraeli, PhD, and his lab in the Department of Developmental Biology and Cancer Research at the Hebrew University of Jerusalem. The ICRF-LCRF Project Grant is a three-year, $180,000 award.